drugset
drugset / Trial / NCT05998304

ADME Study of [14C] Yiqibuvir in Healthy Male Subjects

NCT05998304 ↗

Phase 1 Completed 8 enrolled Sunshine Lake Pharma Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] Yiqibuvir.

Timeline

Start
2023-08-07
Primary completion
2023-09-12
Completion
2023-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Yiqibuvir Unknown 600 mg Oral

Indications

No indication recorded.